

Giacomo Boccuzzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9202131/publications.pdf>

Version: 2024-02-01

74
papers

2,945
citations

279798

23
h-index

175258

52
g-index

88
all docs

88
docs citations

88
times ranked

5126
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 66-73.	0.8	3
2	Impact of Left Ventricular Ejection Fraction on Procedural and Long-Term Outcomes of Bifurcation Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2022, 172, 18-25.	1.6	4
3	Impact of Successful Chronic Coronary Total Occlusion Recanalization on Recurrence of Ventricular Arrhythmias in Implantable Cardioverter-Defibrillator Recipients for Ischemic Cardiomyopathy (VACTO PCI Study). <i>Cardiovascular Revascularization Medicine</i> , 2022, 43, 104-111.	0.8	7
4	Pulmonary Artery Catheter Monitoring in Patients with Cardiogenic Shock: Time for a Reappraisal?. <i>Cardiac Failure Review</i> , 2022, 8, e15.	3.0	12
5	Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E227-E236.	1.7	6
6	Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1143-1150.	1.5	1
7	Cerebral protection in left atrial appendage closure in the presence of appendage thrombosis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 511-515.	1.7	17
8	Short term outcomes of Impella in cardiogenic shock: A review and meta-analysis of observational studies. <i>International Journal of Cardiology</i> , 2021, 324, 44-51.	1.7	40
9	Catheterization laboratory activity before and during COVID-19 spread: A comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE). <i>International Journal of Cardiology</i> , 2021, 323, 288-291.	1.7	17
10	Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. <i>Lancet, The</i> , 2021, 397, 199-207.	13.7	164
11	Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1171-1182.	2.6	7
12	Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 408-416.	0.7	3
13	Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 696-705.	1.8	28
14	Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 259-269.	2.2	12
15	P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 31-42.	3.0	37
16	Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries. <i>American Heart Journal</i> , 2020, 220, 108-115.	2.7	26
17	Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 1143-1150. <i>Cardiovascular Interventions</i> , 2020, 96, 1156-1171.	1.7	2
18	Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1-9.	1.7	15

#	ARTICLE	IF	CITATIONS
19	Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. American Journal of Cardiology, 2020, 125, 491-499.	1.6	10
20	Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. International Journal of Cardiology, 2020, 301, 200-206.	1.7	26
21	Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion. American Journal of Cardiology, 2020, 134, 83-90.	1.6	18
22	Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.7	5
23	Impact of Kissing Balloon in Patients Treated With Ultrathin Stents for Left Main Lesions and Bifurcations. Circulation: Cardiovascular Interventions, 2020, 13, e008325.	3.9	39
24	An App for complex PCI solutions. European Heart Journal, 2020, 41, 342-344.	2.2	2
25	Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent. Catheterization and Cardiovascular Interventions, 2020, 96, E248-E256.	1.7	1
26	Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy. New England Journal of Medicine, 2020, 383, 88-89.	27.0	873
27	Dual antiplatelet therapy strategies and clinical outcomes in patients treated with polymer-free biolimus A9-coated stents. EuroIntervention, 2020, 15, e1358-e1365.	3.2	5
28	Angiographic control versus ischaemia-driven management of patients undergoing percutaneous revascularisation of the unprotected left main coronary artery with second-generation drug-eluting stents: rationale and design of the PULSE trial. Open Heart, 2020, 7, e001253.	2.3	1
29	A Sex-Based Analysis From the RAIN-CARDIOGROUP VII Study (VeRy Thin Stents for Patients With Left) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 342-346.	0.4	3
30	Incidencia anual de trombosis del stent confirmadas y factores clínicos predictores en pacientes con SCA tratados con ticagrelor o prasugrel. Revista Espanola De Cardiologia, 2019, 72, 298-304.	1.2	4
31	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion. JACC: Cardiovascular Imaging, 2019, 12, 934-936.	5.3	3
32	Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry. American Journal of Cardiovascular Drugs, 2019, 19, 381-391.	2.2	16
33	Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAln or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	1.7	5
34	Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. European Heart Journal Cardiovascular Imaging, 2019, 20, 1418-1428.	1.2	5
35	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). American Journal of Cardiology, 2019, 123, 1610-1619.	1.6	20
36	Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 536-542.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Diagnostic accuracy of functional, imaging and biochemical tests for patients presenting with chest pain to the emergency department: A systematic review and meta-analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 412-420.	1.0	13
38	Utilidad de la puntuación PARIS para evaluar el equilibrio isquémico-hemorrágico con ticagrelor y prasugrel tras un síndrome coronario agudo. <i>Revista Española De Cardiología</i> , 2019, 72, 215-223.	1.2	6
39	Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 524-531.	1.2	29
40	Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study. <i>International Journal of Cardiology</i> , 2018, 250, 80-85.	1.7	14
41	Planned angiographic control versus clinical follow-up for patients with unprotected left main stem stenosis treated with second generation drug-eluting stents: A propensity score with matching analysis from the FAILS (failure in left main with second generation stents-CARDIOGROUP III Study). <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E271-E277.	1.7	7
42	Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry. <i>International Journal of Cardiology</i> , 2018, 273, 29-33.	1.7	15
43	Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. <i>European Heart Journal</i> , 2018, 39, 2448-2456.	2.2	44
44	Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry. <i>Thrombosis Research</i> , 2018, 167, 142-148.	1.7	19
45	Clinical impact of optical coherence tomography findings on culprit plaque in acute coronary syndrome: The OCT-FORMIDABLE study registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E486-E492.	1.7	7
46	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2018, 392, 835-848.	13.7	215
47	Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation) <i>Tj ETQq1 1 0.7843146 BT / Overlock 10</i>	1.6	12
48	Radial Versus Femoral Access for the Treatment of Left Main Lesion in the Era of Second-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2017, 120, 33-39.	1.6	12
49	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	2.8	132
50	In-Hospital and 1-Year Outcomes of Rotational Atherectomy and Stent Implantation in Patients With Severely Calcified Unprotected Left Main Narrowings (from the Multicenter ROTATE Registry). <i>American Journal of Cardiology</i> , 2017, 119, 1331-1337.	1.6	19
51	Impact of an optical coherence tomography guided approach in acute coronary syndromes: A propensity matched analysis from the international FORMIDABLE-CARDIOGROUP IV and USZ registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E46-E52.	1.7	26
52	Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions. <i>EuroIntervention</i> , 2017, 13, 355-363.	3.2	15
53	One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). <i>EuroIntervention</i> , 2017, 13, 424-431.	3.2	15
54	Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multicenter registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 881-889.	1.7	38

#	ARTICLE	IF	CITATIONS
55	Rotational atherectomy in very long lesions: Results for the ROTATE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E164-E172.	1.7	39
56	Biolimus-Eluting Stent For de-novo coronary artery disease in patients with Diabetes mellitus. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 729-735.	1.5	1
57	Single-Stage Compared With Multi-Stage PCI in Multivessel NSTEMI Patients. <i>Journal of the American College of Cardiology</i> , 2016, 67, 264-272.	2.8	121
58	Rotational Atherectomy in acute coronary syndrome: early and midterm outcomes from a multicentre registry. <i>EuroIntervention</i> , 2016, 12, 1457-1464.	3.2	43
59	In-hospital and midterm clinical outcomes of rotational atherectomy followed by stent implantation: the ROTATE multicentre registry. <i>EuroIntervention</i> , 2016, 12, 1448-1456.	3.2	49
60	Eroded Versus Ruptured Plaques at the Culprit Site of STEMI. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 566-575.	5.3	88
61	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 373, 997-1009.	27.0	334
62	Evidence from the Resorbable-polymer stent versus Unresorbable-polymer stent Deployment for coronary Intervention: (RUDI-2) registry. <i>International Journal of Cardiology</i> , 2014, 172, 472-475.	1.7	5
63	Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES versus BMS alone to Eliminate Restenosis (CEREA-DES). <i>European Heart Journal</i> , 2013, 34, 1740-1748.	2.2	21
64	Retrospective multicenter observational study of the interventional management of coronary disease in the very elderly: The NINETY. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 414-421.	1.7	10
65	Intravascular ultrasound-guided rotational atherectomy for heavily calcified renal artery stenosis. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 338-342.	1.5	0
66	Immunosuppressive Therapy with Oral Prednisone to Prevent Restenosis after PCI. A Multicenter Randomized Trial. <i>American Journal of Medicine</i> , 2011, 124, 434-443.	1.5	29
67	Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 51-62.	2.9	29
68	Cardiac septal umbrella for closure of a tracheoesophageal fistula. <i>Endoscopy</i> , 2010, 42, E318-E319.	1.8	28
69	A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) – study design and rationale. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 192-199.	1.5	5
70	Percutaneous transcatheter balloon valvuloplasty for severe tricuspid valve stenosis in Ebstein's anomaly. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 510-515.	1.5	2
71	Pregnancy and Heart Disease. , 2009, , 1239-1266.		2
72	Comparison of frequency of insulin resistance after coronary stenting in patients with type 2 diabetes mellitus with versus without coronary restenosis. <i>American Journal of Cardiology</i> , 2004, 94, 777-780.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Giant aneurysm of circumflex coronary artery in asymptomatic patient. Italian Journal of Medicine, 0, 10, .	0.3	0
74	Cardiac Percutaneous Intervention and Surgery During Pregnancy. , 0, , 304-315.		2